The Festival of Biologics Europe, held from 13 to 15 October, brought together pharmaceutical and biotechnology industry professionals, regulators, investors, academics, and start-ups in Basel to share knowledge and explore the latest developments and advances in the field of biologics.
Recognised as Europe’s largest biologics event, the conference welcomed more than 3,000 attendees, 150 exhibitors, and 100 start-ups, with a three-day programme featuring presentations, roundtable discussions, and workshops. Topics addressed included cell and gene therapies, immunotherapies, and biosimilars.
SPEEDCELL, featured in the scientific poster presentations
As part of the conference, members of HIPRA’s Human Health R&D team showcased the SPEEDCELL project through a scientific poster aimed at an international audience of pharmaceutical and biotechnology professionals. The poster outlined the project’s rationale and objectives, as well as the European Union’s 100 Days Mission initiative.
“Within SPEEDCELL, we are working to ensure that faster development goes hand in hand with a strong understanding of product quality and process performance, helping translate innovation into robust and scalable solutions.”, said Núria Casas, Human Health R&D Manager at HIPRA.
Paloma Velasco, Human Health R&D Researcher at HIPRA, added: “The integration of analytical capabilities into accelerated development workflows can help ensure that speed and quality evolve together, rather than being treated as competing priorities.”
One of the key takeaways from the Festival of Biologics is that accelerating the development of biological products is not just about making processes faster, but also about generating better data to support faster and more confident decision-making.
Participation in international events like this helps connect SPEEDCELL’s research with the wider scientific community, fostering the exchange of scientific and technical knowledge.